Patients with personal history of colon cancer can generally receive GLP-1 agonists if otherwise appropriate, as no evidence suggests these drugs increase recurrence risk
More research is needed, especially to determine whether improvements are due to weight loss itself or the direct effects of the drug
This may resemble kidney dysfunction but often reflects normal muscle metabolism
A potential trial will require large sample sizes and a lengthy duration
The sample size was corrected according to the 1,283 students who were enrolled in the Faculty of Chemical Sciences and an expected non-response rate of 30%
In 2024, Blue Cross Blue Shield of Michigan, the states largest nonprofit insurer, and North Carolina's state employee public insurance agency stopped covering the drugs for weight loss, saying the cost increased premiums for all customers